MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

– Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects – NEW YORK, Oct. 4, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the initiation…

Source